The Project Veritas Document Was Real; The Research Overall Originated With D.R.A.S.T.I.C
No, it was not about "viruses" it was about vaccines. For the BATS. To develop aerosolized and transdermal spike protein vaccines for bats in China. Ask yourself: Why?
I spent the entire day studying the Project Veritas document drop that has us all shocked, confused, and to varying degrees, distrustful. Many wondered if it was real, if Project Veritas was being “played,” if it was part of a deeper, sinister agenda to push virus panic, and so forth. I want to say just a few things, from my frustrating research dive. First of all, very few people are sourcing it correctly. It actually has deep roots, and goes way back.
Then, go here.
You will see that NIH awarded its first grant to EcoHealthAlliance toward “Understanding the Risk of Bat Coronavirus Emergence,” in May of 2014.
2014 May 27
Award to EHA of NIH R01Al110964 grant (‘‘Understanding the Risk of Bat Coronavirus Emergence’’) for 5 years (June 2014 - May 2019) - with subgrants to WIV, East China Normal University (Shanghai) and (starting year 3) Wuhan University.1
The clarification came for me here, when I saw what was going on with the bats. They were developing aerosolized and transdermal vaccines for the bats, for one thing. Here, read for yourself:
5. EHA PLANNED TO INOCULATE WILD BATS WITH AEROSOLIZED VACCINES
The proposal for wide scale inoculation of bats in the wild using aerosolized inoculum delivery has never been publicly released or opened to the wider scientific community for discussion as to potential risks associated with this plan.
This is a specialist area of research of Dr Rocke, Dr. Ainslie and Dr. Unidad (PARC) who have previously researched and developed the technological solutions necessary to make this possible:
Dr. Jerome Unidad is a researcher PARC, (2018a) at PARC (owned by Xerox) (PARC, 2018d), who developed the Filament Extension Atomizer (FEA) (PARC, 2019). This technology is used to spray bats with scalable high viscosity mists that stick to their skin or that are edible (PARC, 2018c).
PARC previously partnered with NHWC to develop a vaccine for White Nose Syndrome (WNS) for US bats, using FEA as the technological solution to administer vaccines via aerosol delivery (PARC, 2018b).
Dr. Tonie Rocke is a researcher at USGS National Wildlife Health Centre (NWHC in the DEFUSE proposal). She has previously worked on transdermal application of vaccines against rabies in vampire bats ``The feasibility of controlling rabies in vampire bats through topical application of vaccines” (USFWS, 2019), also “Infectivity of attenuated poxvirus vaccine vectors and immunogenicity of a raccoon pox vectored rabies vaccine in the Brazilian Free-tailed bat” (Stading et al., 2016). There were doubts and concerns about her work:
“These vaccine candidates use a viral vector (attenuated raccoon poxvirus, RCN) genetically modified to express highly-conserved fungal and specific Pd antigens. While these vaccines and other potential treatments continue to be developed, there is a need for safe and effective methods of treatment delivery” (USFWS, 2019).
Another similar project:
“We recently developed a new recombinant rabies vaccine specifically for bats with available sequences from the rabies Phylogroup I glycoprotein. This sequence was cloned into raccoon pox virus (RCN) and the efficacy of this novel RCN-MoG vaccine was tested in big brown bats. Field studies are currently being conducted in Peru and Mexico to test the feasibility of oral and topical delivery of vaccine and transfer rates between vampire bats using biomarker-labelled jelly (without vaccine)” EEFMVZ (2021).
Dr. Ainslie is a Professor at the UNC Department of Biomedical Engineering and the UNC Department of Microbiology and Immunology (Pharmacy UNC, 2021), who works on new polymers for vaccines and electrospray for fabrication of immune targeting microparticles (nanoparticles).
Her publications include “Historical Perspective of Clinical Nano and Microparticle Formulations for Delivery of Therapeutics'' (Batty et al., 2021), “Electrospray for generation of drug delivery and vaccine particles applied in vitro and in vivo” (Steipel et .,2019). “Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine APPLICATIONS'' (Moore et al., 2020), “Considerations for Size, Surface Charge, Polymer Degradation, Co‐Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases” (Genito et al.,2020).
One may contrast this fairly aggressive approach with the one described in a recent paper on ‘Self-disseminating vaccines to suppress zoonoses’. There the recommended approach is to start with captive animals then carefully “perform releases within carefully isolated populations in semi-natural enclosures or on small islands”. More generally concerns have been raised about such self-disseminating vaccines.
DRASTIC - Project DEFUSE HR001118S0017-PREEMPT-FP-019 p. 9/25